Payer Coverage in Polycythemia VeraVideo Categories: Polycythemia Vera
Supported through funding from Incyte
The Most Important Advances in Precision Medicine Being Presented at ASCO 2018
Dr David Spigel reviews 3 of the most important, practice-changing topics at ASCO 2018: new therapies targeting RET in a number of tumor types, a prognostic biomarker assay to predict whether patients with breast cancer will need adjuvant hormonal therapy or chemotherapy, and the minimum level of PD-L1 positivity required [ Read More ]
New Clinical Trial Data Presented at ASCO 2018: How Will it Change How you Practice?
Dr David Spigel discusses the 2 major themes highlighted at ASCO 2018: the use of cancer biomarkers to achieve precision therapy, and fine tuning treatment of patients with immunotherapy with respect to who to treat, how to treat, and how to predict clinical outcomes.